WallStSmart

Bon Natural Life Ltd (BON)vsEcolab Inc (ECL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ecolab Inc generates 86031% more annual revenue ($16.08B vs $18.67M). ECL leads profitability with a 12.9% profit margin vs -10.7%. ECL earns a higher WallStSmart Score of 55/100 (C-).

BON

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: 1.99

ECL

Buy

55

out of 100

Grade: C-

Growth: 6.0Profit: 6.5Value: 4.7Quality: 5.8
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BON.

ECLSignificantly Overvalued (-142.8%)

Margin of Safety

-142.8%

Fair Value

$125.04

Current Price

$268.54

$143.50 premium

UndervaluedFair: $125.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BON2 strengths · Avg: 9.5/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

ECL3 strengths · Avg: 8.7/10
Market CapQuality
$74.91B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Revenue GrowthGrowth
17.8%8/10

17.8% revenue growth

Areas to Watch

BON4 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Market CapQuality
$14.54M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-4.0%2/10

ROE of -4.0% — below average capital efficiency

ECL4 concerns · Avg: 3.3/10
P/E RatioValuation
36.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.4x4/10

Trading at 11.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
2.732/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BON

The strongest argument for BON centers on Price/Book, Debt/Equity.

Bull Case : ECL

The strongest argument for ECL centers on Market Cap, Return on Equity, Revenue Growth. Revenue growth of 17.8% demonstrates continued momentum.

Bear Case : BON

The primary concerns for BON are Altman Z-Score, Market Cap, Piotroski F-Score.

Bear Case : ECL

The primary concerns for ECL are P/E Ratio, Price/Book, Piotroski F-Score.

Key Dynamics to Monitor

BON profiles as a turnaround stock while ECL is a growth play — different risk/reward profiles.

ECL carries more volatility with a beta of 0.98 — expect wider price swings.

ECL is growing revenue faster at 17.8% — sustainability is the question.

ECL generates stronger free cash flow (758M), providing more financial flexibility.

Bottom Line

ECL scores higher overall (55/100 vs 29/100) and 17.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bon Natural Life Ltd

BASIC MATERIALS · SPECIALTY CHEMICALS · China

Bon Natural Life Limited is dedicated to the research and development, manufacture and sale of functional active ingredients extracted from natural herbal plants. The company is headquartered in Cayman Islands.

Ecolab Inc

BASIC MATERIALS · SPECIALTY CHEMICALS · USA

Ecolab Inc., headquartered in St. Paul, Minnesota, is an American corporation that develops and offers services, technology and systems that specialize in water treatment, purification, cleaning and hygiene in a wide variety of applications. It helps organizations both private market as well as public treat their water, not only for drinking directly, but also for use in food, healthcare, hospitality related safety and industry.

Want to dig deeper into these stocks?